Though checkpoint immunotherapy has seemed to achieve much success in clinic application these days, a huge proportion of patients with RAS-driven tumors are still suffering from resistance to therapy and poor clinical outcomes. In this review, Antonio B. Ward et al reported the potential of RAS inhibitors to enhance or broaden the anticancer activity of currently available checkpoint immunotherapy.

Fig. 1 Oncogenic RAS signaling increases tumor immune evasion.

 

 

 

Article Access: https://onlinelibrary.wiley.com/doi/10.1002/mco2.10

 

 

                                                                           

Website for MedComm: https://onlinelibrary.wiley.com/journal/26882663

Looking forward to your contributions.